Volume 20, Issue 6 (9-2017)
J Arak Uni Med Sci 2017, 20(6): 22-30 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Khoshbin Nazdik M, Khazaei Koohpar Z, Sayad A. Investigation of TIMP-1 Gene Expression in Patients with Multiple Sclerosis(MS). J Arak Uni Med Sci 2017; 20 (6) :22-30
URL: http://jams.arakmu.ac.ir/article-1-4972-en.html
URL: http://jams.arakmu.ac.ir/article-1-4972-en.html
1- Department of Cellular and Molecular Biology, Faculty of Biological Sciences,Tonekabon Branch, Islamic Azad University, Tonekabon, Iran
2- PhD in Cellular and Molecular Biology, Department of Cellular and Molecular Biology, Faculty of Biological Sciences,Tonekabon Branch, Islamic Azad University, Tonekabon, Iran. , khazaei@toniau.ac.ir
3- PhD in Medical Genetic, Department of Medical Genetic, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2- PhD in Cellular and Molecular Biology, Department of Cellular and Molecular Biology, Faculty of Biological Sciences,Tonekabon Branch, Islamic Azad University, Tonekabon, Iran. , khazaei@toniau.ac.ir
3- PhD in Medical Genetic, Department of Medical Genetic, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract: (4436 Views)
Abstract
Background: Matrix metalloproteinases (MMPs) comprise a family of proteolytic enzymes.MMPs are capable of disrupting the blood-brain barrier (BBB), mediating the destruction of extracellular matrix and myelin components. Tissue inhibitors of metalloproteinases (TIMPs) are proteins which block the activitiy of MMPs. Matrix metalloproteinase-9 (MMP-9) facilitates T-cell migration into the CNS while the tissue inhibitor matrix metalloproteinase-1 (TIMP-1) inhibits MMP-9 actions. The aim of this study was to evaluate the expression of TIMP-1 gene (in RNA level) in blood cells of relapsing-remitting multiple sclerosis (RRMS) patients treated with IFNb.
Materials and Methods: In this study, the expression level of TIMP-1 gene was investigated in blood cells of MS patients compared to healthy subjects by Real-Time PCR.
Results: The RRMS patients manifested a lower expression level of TIMP-1 RNA than their normal counterparts, although the result was not significant (p=0.1).
Conclusion: The results of this study showed that there was no linear correlation between TIMP-1 expression level and risk of Expanded Disability Status Scale of Kurtzke (EDSS); nor was there any significant correlation between expression status of TIMP-1 and duration of the disease. Further studies are recommended to compare TIMP-1 RNA in patients before and after taking IFN-beta.
Background: Matrix metalloproteinases (MMPs) comprise a family of proteolytic enzymes.MMPs are capable of disrupting the blood-brain barrier (BBB), mediating the destruction of extracellular matrix and myelin components. Tissue inhibitors of metalloproteinases (TIMPs) are proteins which block the activitiy of MMPs. Matrix metalloproteinase-9 (MMP-9) facilitates T-cell migration into the CNS while the tissue inhibitor matrix metalloproteinase-1 (TIMP-1) inhibits MMP-9 actions. The aim of this study was to evaluate the expression of TIMP-1 gene (in RNA level) in blood cells of relapsing-remitting multiple sclerosis (RRMS) patients treated with IFNb.
Materials and Methods: In this study, the expression level of TIMP-1 gene was investigated in blood cells of MS patients compared to healthy subjects by Real-Time PCR.
Results: The RRMS patients manifested a lower expression level of TIMP-1 RNA than their normal counterparts, although the result was not significant (p=0.1).
Conclusion: The results of this study showed that there was no linear correlation between TIMP-1 expression level and risk of Expanded Disability Status Scale of Kurtzke (EDSS); nor was there any significant correlation between expression status of TIMP-1 and duration of the disease. Further studies are recommended to compare TIMP-1 RNA in patients before and after taking IFN-beta.
Type of Study: Original Atricle |
Subject:
Basic Sciences
Received: 2017/03/3 | Accepted: 2017/07/19
Received: 2017/03/3 | Accepted: 2017/07/19
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
